Recent advances in targeted advanced lung cancer therapy in the elderly

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997;33(14):2313–2314.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Gridelli C, van Meerbeeck JP, et al. EORTC elderly task force and lung cancer group and international society for geriatric oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol. 2010;21(4):692–706.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Kohne CH, Cohen HJ, et al. Never too old? Age should not be a barrier o enrolment in cancer clinical trials. Oncologist. 2005;10(3):198–204.
   PubMed Web of Science ®Google Scholar
• Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in the older cancer patients: clinical and economic considerations. Cancer Control. 2000;7:539–547.
   PubMedGoogle Scholar
• Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial. J Clin Oncol. 2001;19(13):3210–3218.
   PubMed Web of Science ®Google Scholar
• Johnson DH. Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern cooperative oncology group. J Natl Inst Monogr. 1995;19:61–63.
   Google Scholar
• Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2010;21(3):540–547.
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer leukemia group B (study 9730). J Clin Oncol. 2005;23(1):190–196.
   PubMed Web of Science ®Google Scholar
• Tyagi P. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial. Clin Lung Cancer. 2005;6(5):276–278.
   PubMedGoogle Scholar
• Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. The Oncologist. 2001;6(suppl1):4–7.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95(5):362–372.
   PubMed Web of Science ®Google Scholar
• Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: ICFT-0501 randomised, phase 3 trial. Lancet. 2011;378(9796):1079–1088.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines, 2nd and. Chest. 2007;132(3 Suppl):277S–289S.
   PubMed Web of Science ®Google Scholar
• Hickish TF, Smith IE, O’Brien ME, et al. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer. 1998;78(1):28–33.
   PubMed Web of Science ®Google Scholar
• Kaneda H, Tamura K, Kurata T. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib patients with advanced non-small-cell lung cancer. Lung Cancer. 2004;46(2):247–254.
   PubMed Web of Science ®Google Scholar
• Tam TC, Ho JC, Wong MK, et al. Treatment outcomes in elderly with advanced-stage non-small cell lung cancer. Lung. 2013;191:645–654.
   PubMed Web of Science ®Google Scholar
• Crinò L, Cappuzzo F, Zatluokal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008;26(26):4253–4260.
   PubMed Web of Science ®Google Scholar
• Chen KY, Chen JH, Shih JY, et al. Octogenarians with advanced non-small cell lung cancer: treatment modalities, surviva, and prognostic factors. J Thorac Oncol. 2010;5(1):82–89.
   PubMed Web of Science ®Google Scholar
• Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315:971–979.
   PubMed Web of Science ®Google Scholar
• Zaarour M, Weerasinghe C, Nazha B, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer. Expert Rev Anticancer Ther. 2015;15(11):1327–1336.
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor if the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158.
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–1818.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Bjc. 2014;110:55–62.
   PubMed Web of Science ®Google Scholar
• Kuwako T, Imai H, Masuda T, et al. First-line gefitinib treatment in elderly patients (aged > 75 years) with non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol. 2015;76(4):761–769.
   PubMed Web of Science ®Google Scholar
• Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-pacliaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–128.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
   PubMed Web of Science ®Google Scholar
• Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122–1128.
   PubMed Web of Science ®Google Scholar
• Tateishi K, Ichiyama T, Hirai K, et al. Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study. Med Oncol. 2013;30(1):450.
   PubMed Web of Science ®Google Scholar
• Morikawa N, Minegishi Y, Inoue A, et al. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opin Pharmacother. 2015;16(4):465–472.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Saito H, Hasegawa Y, et al. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901. Cancer Chemother Pharmacol. 2014;74(4):721–727.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations. J Thorac Oncol. 2012;7:1417–1422.
   PubMed Web of Science ®Google Scholar
• Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394–1400.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802). Lancet Oncol. 2011;12:735–742.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcenery E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–246.
   PubMed Web of Science ®Google Scholar
• Lee SM, Khan I, Upadhyay S, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13:1161–1170.
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Komuta K, Imamura F, et al. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer. Lung Cancer. 2014;86:201–206.
   PubMed Web of Science ®Google Scholar
• Yamada K, Azuma K, Takeshita M, et al. Phase II trial of erlotinib in elderly patients with previously treated non-small cell lung cancer: results of the Lung Oncology Group in Kyushu (LOGiK-0802). Anticancer Res. 2016;36(6):2881–2887.
   PubMed Web of Science ®Google Scholar
• Bigot F, Boudou-Rouquette P, Arrondeau J, et al. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. Invest New Drugs. 2017;35:242.
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27:4702–4711.
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343:342–350.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327–3334.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213–222.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-lung 3: a phase IIIstudy of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3342–3350.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): the analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–151.
   PubMed Web of Science ®Google Scholar
• Fein L, Wu Y-L, Sequist LV, et al. Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged > 65 years: subgroup analysis of LUX-Lung 3/6. J Thor Oncol. 2016;11(10S):S202–S203. abstract P1.33.
   PubMedGoogle Scholar
• Park K, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment for patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577–589.
   PubMed Web of Science ®Google Scholar
• Kashiwabara K, Semba H, Fujii S, et al. Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer. Respir Investig. 2016;54(6):468–472.
   PubMedGoogle Scholar
• Okaushi S, Hagimoto S, Osawa H, et al. Afatinib for an elderly patient with chronic kidney disease. Eur Ger Med. 2017;8(2):104.
   Web of Science ®Google Scholar
• Stopler P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69:1051–1061.
   PubMed Web of Science ®Google Scholar
• Ongoing trial, recruiting participants: Afatinib treatment for patients with EGFR mutation positive NSCLC who are age 70 or older. [cited 2017 Apr 8]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02514174?view=record
   Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancer acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Ji W, Choi CM, Rho JK, et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013;13:606.
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acuired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247.
   PubMed Web of Science ®Google Scholar
• Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66(16):7854–7858.
   PubMed Web of Science ®Google Scholar
• Li H, Hu H, Wang R, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014;7:513–524.
   PubMed Web of Science ®Google Scholar
• Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine-kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–440.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Kawaguchi T, Isa S, et al. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res. 2015;21(15):3552–3560.
   PubMed Web of Science ®Google Scholar
• Costa C, Molina MA, Drozdowskyj A, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014;20(7):2001–2010.
   PubMed Web of Science ®Google Scholar
• Janne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804 in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17(5):1131–1139.
   PubMed Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, et al. Phase I trial of the EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965–3972.
   PubMed Web of Science ®Google Scholar
• Gao X, Le X, Costa DB. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation-positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16(4):383–390.
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP, Wilmington DE, editor. TAGRISSO (TM).
   Google Scholar
• Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–1652.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC-H, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–1699.
   PubMed Web of Science ®Google Scholar
• Yang JC-H, Ahn MJ, Kim D-W, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017 Feb 21;JCO2016703223. DOI:10.1200/JCO.2016.70.3223
   Web of Science ®Google Scholar
• Ongoing study: AZD9291 versus gefitinib or erlotinib in patients with locally advanced or metastatic non-small cell lung cancer (FLAURA). [cited 2017 Apr 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02296125?term=flaura&rank=1
   Google Scholar
• Ongoing trial, recruiting participants: Real world treatment study of AZD9291 for advanced/metastatic EGFR T790M mutation NSCLC (ASTRIS). [cited 2017 Apr 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02474355?term=astris&rank=1
   Google Scholar
• Trial not yet open: Open label, prospective study to investigate efficacy and safety of AZD9291 in BM from NSCLC patients with EGFR T790M. [cited 2017 Apr 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02972333?term=astris&rank=2
   Google Scholar
• Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lynphoma kinase: signalling in development and disease. Biochem J. 2009;420:345–361.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68:68–94.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6:3314–3322.
   PubMed Web of Science ®Google Scholar
• Ou S-HI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual MesenchymalEpithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942–946.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl Med. 2010;363:1693–1703.
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancer. J Clin Oncol. 2012;30:863–870.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–2177.
   PubMed Web of Science ®Google Scholar
• Blackhall F, Shaw A, Janne PA, et al. Crizotinib safety profile in elderly and non-elderly patients with advanced ALK+ non-small cell lung cancer. Proc IASCL. 2013. abstr P1.11-017.
   Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lug cancers. Sci Trasl Med. 2012;4:120ra17.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistace to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472–1482.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present and future. J Clin Oncol. 2013;31:1105–1111.
   PubMed Web of Science ®Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (LAK) inhibitor 5-chloro-N2-(2-iisopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,3-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56:5675–5690.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–1197.
   PubMed Web of Science ®Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small-cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). ASCO Annual Meeting 2015. Journal of Clinical Oncology. May 2015;33:15_suppl (8059-8059). doi: 10.1200/jco.2015.33.15_suppl.8059.
   Google Scholar
• Felip E, Orlov S, Park K, et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small-cell lung cancer (NSCLC). ASCO Annual Meeting 2015. Journal of Clinical Oncology. May 2015;33:15_suppl (8060-8060). doi: 10.1200/jco.2015.33.15_suppl.8060.
   Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14:590–598.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119–1128.
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open label, randomised phase 3 trial. Lancet. 2017 May 10. pii: S0140-6736(17)30565-2. DOI:10.1016/S0140-6736(17)30565-2
   Web of Science ®Google Scholar
• Shaw A, Peters S, Mok T, et al. Alectinib vs crizotinib in treatment-naive advanced ALK+ NSCLC: primary results of the global phase III ALEX study (LBA 9008). ASCO Annual Meeting in Chicago; 2-6 June 2017.
   Google Scholar
• Le Saux O, Falandry C, Gan HK, et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol. 2016;27:1799–1804.
   PubMed Web of Science ®Google Scholar
• Roviello G, Zanotti L, Cappelletti MR, et al. Are EGFR tyrosine kinase inhibitors effective in elderly patients with EGFR-mutated non-small cell lung cancer? Clin Exp Med. 2017;Apr 8. DOI:10.1007/s10238-017-0460-7
   PubMedGoogle Scholar